We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
+49.01%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.43B
AUM Growth
-$263M
(-15%)
Cap. Flow
-$141M
Cap. Flow
% of AUM
-9.8%
Top 10 Holdings %
Top 10 Hldgs %
54.7%
Holding
66
New
3
Increased
9
Reduced
40
Closed
4
Top Buys
| 1 |
Neurogene
NGNE
|
+$13.2M |
| 2 |
CBLL
CeriBell Inc
CBLL
|
+$11.9M |
| 3 |
RAPT
RAPT Therapeutics
RAPT
|
+$9.48M |
| 4 |
LivaNova
LIVN
|
+$8.64M |
| 5 |
SLN
Silence Therapeutics
SLN
|
+$6.45M |
Top Sells
| 1 |
AUGX
Augmedix, Inc. Common Stock
AUGX
|
+$38.5M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
+$36.1M |
| 3 |
Scholar Rock
SRRK
|
+$22.4M |
| 4 |
Kymera Therapeutics
KYMR
|
+$13.2M |
| 5 |
FOLD
Amicus Therapeutics
FOLD
|
+$12.4M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Scholar Rock
SRRK
$6.46B
| $197M | 13.7% |
4,549,881
-688,956
| -13% | -$22.4M |
|
2
Krystal Biotech
KRYS
$10.2B
| $118M | 8.22% |
753,175
-57,070
| -7% | -$10.1M |
|
3
Nurix Therapeutics
NRIX
$2.45B
| $79M | 5.51% |
4,192,627
-88,354
| -2% | -$2.03M |
|
4
Zymeworks
ZYME
$1.81B
| $70.9M | 4.94% |
4,840,463
-261,448
| -5% | -$3.66M |
|
|
FOLD
5
DELISTED
Amicus Therapeutics
FOLD
| $66.5M | 4.63% |
7,054,890
-1,191,702
| -14% | -$12.4M |
|
6
Replimune Group
REPL
$824M
| $59.4M | 4.14% |
4,905,527
+124,344
| +3% | +$1.51M |
|
7
Immunome
IMNM
$2.53B
| $51.3M | 3.57% |
4,828,026
-61,528
| -1% | -$744K |
|
8
Stoke Therapeutics
STOK
$1.83B
| $50.7M | 3.53% |
4,593,629
-119,880
| -3% | -$1.47M |
|
|
9
LivaNova
LIVN
$4.41B
| $48.3M | 3.37% |
1,043,539
+168,500
| +19% | +$8.64M |
|
|
10
Kymera Therapeutics
KYMR
$9.27B
| $44.3M | 3.09% |
1,100,432
-292,824
| -21% | -$13.2M |
|
11
Pliant Therapeutics
PLRX
$68.7M
| $38.1M | 2.66% |
2,895,478
-302,013
| -9% | -$4.12M |
|
12
Beam Therapeutics
BEAM
$3.12B
| $37.9M | 2.64% |
1,528,567
-82,446
| -5% | -$2.1M |
|
13
Regenxbio
RGNX
$621M
| $37.1M | 2.58% |
4,794,780
-98,122
| -2% | -$921K |
|
|
AKRO
14
DELISTED
Akero Therapeutics
AKRO
| $34.4M | 2.39% |
1,235,209
-152,270
| -11% | -$4.61M |
|
15
Biohaven
BHVN
$2.21B
| $33.8M | 2.35% |
904,496
-129,723
| -13% | -$6.05M |
|
16
Annexon
ANNX
$931M
| $32.3M | 2.25% |
6,300,644
-126,818
| -2% | -$780K |
|
17
ADC Therapeutics
ADCT
$156M
| $31.2M | 2.17% |
15,666,731
-2,486
| -0% | -$6.5K |
|
|
18
Neurogene
NGNE
$779M
| $30.2M | 2.1% |
1,319,763
+355,416
| +37% | +$13.2M |
|
19
Boston Scientific
BSX
$64.6B
| $27.9M | 1.95% |
312,683
-18,190
| -5% | -$1.6M |
|
20
Cogent Biosciences
COGT
$6.67B
| $27.7M | 1.93% |
3,554,836
-929,544
| -21% | -$9.26M |
|
21
Absci
ABSI
$1.66B
| $21.6M | 1.51% |
8,253,316
| – | – |
|
22
Fate Therapeutics
FATE
$336M
| $21.2M | 1.48% |
12,872,946
-296,111
| -2% | -$746K |
|
|
IGMS
23
DELISTED
IGM Biosciences
IGMS
| $18M | 1.26% |
2,952,131
-120,347
| -4% | -$1.43M |
|
|
ETNB
24
DELISTED
89bio
ETNB
| $16.9M | 1.18% |
2,167,176
+597,326
| +38% | +$4.92M |
|
|
SLN
25
Silence Therapeutics
SLN
$487M
| $16.5M | 1.15% |
2,399,317
+500,000
| +26% | +$6.45M |
|
Similar funds
ORI
GAI
HCMG
FMI
FCM
PP
AM
BFO